Mesoblast Price To Sales Ratio from 2010 to 2025

MESO Stock  USD 17.15  1.61  10.36%   
Mesoblast Price To Sales Ratio yearly trend continues to be very stable with very little volatility. Price To Sales Ratio is likely to drop to 121.78. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Mesoblast's market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
128.19
Current Value
121.78
Quarterly Volatility
96.28596163
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Latest Mesoblast's Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Mesoblast over the last few years. Price to Sales Ratio is figured by comparing Mesoblast stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Mesoblast sales, a figure that is much harder to manipulate than other Mesoblast multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Mesoblast's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 385.79 X10 Years Trend
Pretty Stable
   Price To Sales Ratio   
       Timeline  

Mesoblast Price To Sales Ratio Regression Statistics

Arithmetic Mean103.47
Geometric Mean71.51
Coefficient Of Variation93.06
Mean Deviation64.74
Median83.57
Standard Deviation96.29
Sample Variance9,271
Range324
R-Value(0.22)
Mean Square Error9,468
R-Squared0.05
Significance0.42
Slope(4.37)
Total Sum of Squares139,065

Mesoblast Price To Sales Ratio History

2025 121.78
2024 128.19
2023 111.47
2022 70.81
2021 25.36
2020 114.39
2019 35.55

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as Price To Sales Ratio, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Sales Ratio 128.19  121.78 
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.